Journal of Applied Biomedicine, 2014 (vol. 12), issue 1

Contents

J Appl Biomed 12:v, 2014 | DOI: 10.1016/S1214-021X(13)00021-5  

Circadian haematotoxicity of the antiepileptic valproic acid in mice

Wafa Ben-Cherif, Ichrak Dridi, Mohsen Hassine, Mossadok Ben-Attia, Karim Aouam, Alain Reinberg, Naceur Boughattas

J Appl Biomed 12:31-38, 2014 | DOI: 10.1016/j.jab.2013.04.001  

Antiepileptic drugs may have varying toxicity or efficacy depending on administration time. VPA administration could be associated with a great deal of haematological toxicity and can cause aplasic anaemia or peripheral cytopenia affecting one or more cell lines. The objective of this study is to experimentally verify if VPA-induced haematological toxicity in mice varies according to drug administration time in the 24 h scale. Different groups of mice received 620 mg/kg of VPA by i.p. route at four different circadian stages. The results obtained showed that VPA treatment induced a significant decrease in the haematological parameter rates (cytopenia)...

Fate of two types of cerebellar graft in wild type and cerebellar mutant mice

Miroslava Čedíková, Zbyněk Houdek, Václav Babuška, Vlastimil Kulda, František Vožeh, Nicolas Zech, Lenka Černá, Kristýna Krakorová, Milena Králíčková, Jan Cendelín

J Appl Biomed 12:17-23, 2014 | DOI: 10.1016/j.jab.2013.03.001  

The possibility of regeneration in a damaged central nervous system (CNS) is limited and therapy of CNS diseases accompanied with neuronal loss is problematic.Lurcher (Lc) mutant mice represent a model for olivocerebellar degeneration.Heterozygotes suffer from a complete loss of cerebellar Purkinje cells and a secondary reduction of granule cells and inferior olive neuron number.

Entry of oxime K027 into the different parts of rat brain: Comparison with obidoxime and oxime HI-6

Jana Žďárová Karasová, Filip Zemek, Jiří Kassa, Kamil Kuča

J Appl Biomed 12:25-29, 2014 | DOI: 10.1016/j.jab.2013.01.001  

Acetylcholinesterase reactivators (oximes) are highly hydrophilic compounds. This factor is considered to limit their distribution through the human body, especially into the central nervous system. However, some results contradict this hypothesis and confirm low concentrations of oximes inside the CNS. This study aims to verify oxime penetration through the blood-brain barrier, and into different brain regions.It has been confirmed that oximes can penetrate the BBB after therapeutic dose administration (0.73%, 0.69%, and 0.52% corresponding to obidoxime, HI-6, and new oxime K027). Although the whole brain level of K027 seems to be lower compared...

Proenzyme therapy of sarcoma S-180 and melanoma B16-F10

Pavlína Kaiserová, Lucie Kalferstová, Hana Maršíková, Irena Bartoňová, Peter Koník, Jan Kopecký, Jan Ženka

J Appl Biomed 12:39-47, 2014 | DOI: 10.1016/j.jab.2012.11.001  

The aim of this study was to evaluate the effectiveness of individual (inactive) proenzymes and mixtures thereof in cancer treatment and to compare this treatment with more frequently used therapy based on active proteases. Experiments focused on explanation of possible mechanisms of proenzyme action against tumours are included.Proenzyme therapy of sarcoma S-180 significantly reduced tumour growth and prolonged survival of mice. The effect of trypsinogen and chymotrypsinogen was synergistic. Proenzyme therapy of melanoma B16-F10 bearing mice reduced both tumour growth and prevalence of metastases. Active enzyme based therapy of melanoma B16-F10...

Advances in biosensors: Principle, architecture and applications

Veeradasan Perumal, Uda Hashim

J Appl Biomed 12:1-15, 2014 | DOI: 10.1016/j.jab.2013.02.001  

The ability to detect pathogenic and physiologically relevant molecules in the body with high sensitivity and specificity offers a powerful opportunity in the early diagnosis and treatment of diseases. Early detection and diagnosis can be used to greatly reduce the cost of patient care associated with the advanced stages of many diseases. However, despite their widespread clinical use, these techniques have a number of potential limitations. For example, a number of diagnostic devices have slow response times and are burdensome to patients. Furthermore, these assays are expensive and cost the health care industry billions of dollars every year. Therefore,...